Geninus

Geninus EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Geninus (389030.KQ) as of Oct 23, 2026 is -14.58. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -9.67 — a change of 50.74% (lower).

EV/OCF

-14.58

YoY

50.74%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Geninus is 2025 -14.58 . EV/OCF (Enterprise Value to Operating Cash Flow) of Geninus was 2024 -9.67 . It decreases by 50.74% lower compared to the previous year.

The Geninus EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
1,654.21 KRW
Jan 1, 2019
-42.79 KRW
Jan 1, 2020
46.01 KRW
Jan 1, 2021
-6.30 KRW
Jan 1, 2022
-6.09 KRW
Jan 1, 2023
-12.70 KRW
Jan 1, 2024
-9.67 KRW
Jan 1, 2025
-14.58 KRW
The Geninus EV/OCF history
YEAREV/OCFYoY
-14.58+50.74%
-9.67-23.86%
-12.70+108.52%
-6.09-3.31%
-6.30-113.70%
46.01-207.52%
-42.79-102.59%
1,654.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Geninus Stock analysis

What does Geninus do? Geninus Inc. generates revenue through the provision of single cell analysis services and genetic testing for disease prediction to the public. The company develops and manufactures genome analysis solutions, including cancer genome analysis based on tissue biopsy, and offers personal genetic testing services. Additionally, Geninus Inc. engages in software development and a rental business as part of its product portfolio. The primary customers are individuals seeking genetic insights for health management and healthcare providers requiring advanced genomic analysis tools. The company's products include NGS-based genome analysis technology, cancer genome analysis solutions, and personal genetic testing services. These offerings target healthcare institutions, medical professionals, and consumers interested in personalized health assessments. Geninus Inc. also develops software for genomic data processing, which supports its service delivery and rental business model. Revenue streams are derived from direct sales of genome analysis solutions, service fees for single cell and cancer genome analysis, and subscriptions for software and rental services. The firm's focus on NGS technology positions it within the biotechnology sector, serving both clinical and consumer markets with a range of genomic services and products. Geninus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Geninus stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Geninus is -14.58 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Geninus changed from -9.67 to -14.58, representing a 50.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Geninus since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Geninus with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Geninus

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Geninus